Alex Evans, PharmD, MBA.

Research Update

Proposed Treatment Algorithm for Postpartum Psychosis

March 1, 2025

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Zuranolone (Zurzuvae) may be FDA-approved for postpartum depression, but we need a very different medication approach for the 1-2 in 1,000 who develop postpartum psychosis.

Research Update

Lithium, Valproate Have Low (and Similar) Risk of Kidney Injury

November 1, 2024

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Research explores the kidney injury risks associated with lithium compared to valproate, revealing unexpected findings.

Research Update

STAR*D Reanalysis Causes New Debate Over Antidepressant Efficacy

June 1, 2024

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

New analysis questions whether STAR*D followed its own protocols.

Research Update

Do Mood Stabilizers Prevent Death in Bipolar Disorder?

April 1, 2024

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

One mood stabilizer stands out for its lower risk of mortality in bipolar disorder.

DALL·E 2023-11-13 10.39.08 - two people talking.jpg

RESEARCH UPDATE

DBT and Social Rhythm Therapy: A Novel Combination

November 13, 2023

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Here's the latest on combining dialectical behavior therapy with social rhythm therapy for comorbid bipolar disorder and borderline.

Research Update

Surprise Result for Adherence in Bipolar Disorder

November 9, 2023

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Lithium’s reputation as a difficult med may have more to do with branding than reality, according to this large analysis of mood stabilizer adherence.